However, a large gap in regards to AD and GLP-1 based therapies remains, since the small sample size of the study precluded the ability for the study to determine if GLP-1 administration reduces amyloid β (Aβ) load or alter cognitive scores (275). The gene discussed is GLP1R; the disease is Alzheimer disease.